Compare ADMA Biologics Inc (ADMA) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Synchrony Financial — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Synchrony Financial trades at $78.37 (market cap $25.44B). The key difference: Synchrony Financial is far larger — about 11.7× ADMA Biologics Inc's market cap, and Synchrony Financial pays a 1.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SYF | |
|---|---|---|
Market Cap | $2.18B | $25.44B |
Sector | Health | Financials |
52-Week High | $20.38 | $88.47 |
52-Week Low | $7.60 | $63.78 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Synchrony Financial (SYF) trades at $78.59, down 0.1% on the day, with a bullish technical outlook supported by moving averages and strong institutional backing. The stock shows robust fundamentals with a P/E of 8.02, net income margin of 23.4%, and consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.59 versus $2.14 expected. Recent news highlights partnerships like CareCredit's integration with Stripe, enhancing growth prospects.
SYF presents a compelling buy opportunity with a consensus price target of $86.33, offering ~10% upside, driven by aggressive buybacks, stable credit trends, and positive analyst sentiment (62.5% buy ratings). Risks include potential consumer spending slowdowns and competitive pressures in the financial services sector, but strong cash flow and dividend payments support shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
